Signs Of Life In The Bacterial Vaginosis, Vulvovaginal Candidiasis Pipeline

Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.

A few new drug therapies could be on the horizon for some of the most common women’s health infections – vulvovaginal candidiasis and bacterial vaginosis – after years of efforts by the US Food and Drug to incentivize and guide development of new drugs.

Scynexis Inc. touts a “clear regulatory path with high chance of technical success” of ibrexafungerp in vulvovaginal candidiasis (VVC),...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet